Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. Fundamental Analysis
Fuji Pharma Co., Ltd. (4554.T) shows moderate financial fundamentals with a PE ratio of 23.32, profit margin of 4.27%, and ROE of 5.01%. The company generates $54.6B in annual revenue with strong year-over-year growth of 12.01%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 56.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 4554.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4554.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent4554.T trades at attractive valuation levels.
Growth Score
Moderate4554.T shows steady but slowing expansion.
Financial Health Score
Excellent4554.T maintains a strong and stable balance sheet.
Profitability Score
Weak4554.T struggles to sustain strong margins.
Key Financial Metrics
Is 4554.T Expensive or Cheap?
P/E Ratio
4554.T trades at 23.32 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 4554.T's PEG of -1.04 indicates potential undervaluation.
Price to Book
The market values Fuji Pharma Co., Ltd. at 1.13 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.80 times EBITDA. This is generally considered low.
How Well Does 4554.T Make Money?
Net Profit Margin
For every $100 in sales, Fuji Pharma Co., Ltd. keeps $4.27 as profit after all expenses.
Operating Margin
Core operations generate 11.95 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.01 in profit for every $100 of shareholder equity.
ROA
Fuji Pharma Co., Ltd. generates $2.45 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Fuji Pharma Co., Ltd. produces operating cash flow of $5.80B, showing steady but balanced cash generation.
Free Cash Flow
Fuji Pharma Co., Ltd. produces free cash flow of $3.82B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $156.20 in free cash annually.
FCF Yield
4554.T converts 7.02% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
23.32
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.04
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.13
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.64
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.57
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How 4554.T Stacks Against Its Sector Peers
| Metric | 4554.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 23.32 | 28.25 | Better (Cheaper) |
| ROE | 5.01% | 780.00% | Weak |
| Net Margin | 4.27% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.64 | 0.30 | Weak (High Leverage) |
| Current Ratio | 1.57 | 4.66 | Neutral |
| ROA | 2.45% | -14687.00% (disorted) | Weak |
4554.T outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Fuji Pharma Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
95.25%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
83.71%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
28.36%
Industry Style: Defensive, Growth, Innovation
High Growth